ZEB1 and melanoma: Functional studies revealed that ZEB1 overexpression drives melanoma phenotypic plasticity and is sufficient to drive resistance to BRAF and/or MEK inhibitors, whereas ZEB1 inhibition sensitizes naive melanoma cells to BRAF inhibitors, prevents the emergence of resistance, and decreases the viability of resistant cells (Richard et al., 2016).